{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T19:29:04Z","timestamp":1780860544323,"version":"3.54.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:00:00Z","timestamp":1626307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007797","name":"Helsingin Yliopisto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008493","name":"V\u00ef\u00bf\u00bdin\u00ef\u00bf\u00bd  ja Laina Kiven S\u00ef\u00bf\u00bd\u00ef\u00bf\u00bdti\u00ef\u00bf\u00bd","doi-asserted-by":"publisher","award":["202000041"],"award-info":[{"award-number":["202000041"]}],"id":[{"id":"10.13039\/501100008493","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>Non-steroidal anti-inflammatory drug (NSAID)\u2014exacerbated respiratory disease (NERD) is an adult-onset inflammatory condition of the upper and lower airways. It is characterized by the co-existence of asthma, nasal polyposis, and hypersensitivity to NSAIDs. Over one-fourth of patients also have symptoms of chronic middle-ear infection. The clinical course of NERD is often severe and generally requires multimodal treatment with recurrent surgical measures. Studies presenting the disease burden and subjective symptom control of NERD are limited. In this qualitative questionnaire study, we present the clinical characteristics of asthma, nasal polyposis, NSAID intolerance and possible recurrent or chronic middle-ear infection of 66 confirmed NERD patients treated at our tertiary referral center between January 2016 and May 2017. Additionally, we present the patient-reported disease control of asthma, nasal polyposis, and middle-ear symptoms on a four-category Likert scale. The proportion of NERD patients with recurrent or chronic middle-ear infection was 18%. The proportion of good or very good subjective disease control was 83% for asthma, 58% for nasal polyposis, and 33% for chronic middle-ear infection, if present. Chronic middle-ear infection is common among NERD patients and should more often be recognized as part of the entity. Together with nasal polyposis, chronic middle-ear infection seems to affect patients more than asthma. The patient's perspective of disease control should be considered when planning the interdisciplinary follow-up and treatment of NERD.<\/jats:p>","DOI":"10.3389\/falgy.2021.716169","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T05:32:42Z","timestamp":1626327162000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Patient-Reported Control of Asthma, Nasal Polyposis, and Middle-Ear Symptoms in NSAID-Exacerbated Respiratory Disease"],"prefix":"10.3389","volume":"2","author":[{"given":"Anna","family":"Suikkila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Hafr\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annina","family":"Lyly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuomas","family":"Klockars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riitta","family":"Saarinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"975","DOI":"10.7326\/0003-4819-68-5-975","article-title":"Intolerance to aspirin. Clinical studies and consideration of its pathogenesis","volume":"68","author":"Samter","year":"1968","journal-title":"Ann Intern Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/all.13599","article-title":"Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper","volume":"74","author":"Kowalski","year":"2019","journal-title":"Allergy."},{"key":"B3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2500\/ajra.2016.30.4370","article-title":"Aspirin-exacerbated respiratory disease: prevalence, diagnosis, treatment, and considerations for the future","volume":"30","author":"Kennedy","year":"2016","journal-title":"Am J Rhinol Allergy."},{"key":"B4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/medsci7030045","article-title":"Aspirin exacerbated respiratory disease: epidemiology, pathophysiology, and management","volume":"7","author":"Li","year":"2019","journal-title":"Med Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jaci.2014.08.020","article-title":"Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature","volume":"135","author":"Rajan","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2500\/ajra.2015.29.4123","article-title":"Factors driving the aspirin exacerbated respiratory disease phenotype","volume":"29","author":"Steinke","year":"2015","journal-title":"Am J Rhinol Allergy."},{"key":"B7","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1034\/j.1399-3003.2000.016003432.x","article-title":"Natural history of aspirin-induced asthma. AIANE investigators. European network on aspirin-induced asthma","volume":"16","author":"Szczeklik","year":"2000","journal-title":"Eur Respir J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000163218","article-title":"Otologic manifestations in Samter's syndrome","volume":"71","author":"Caversaccio","year":"2009","journal-title":"ORL J Otorhinolaryngol Relat Spec."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.jaip.2018.11.034","article-title":"Hearing loss and middle ear symptoms in aspirin-exacerbated respiratory disease","volume":"7","author":"Mullur","year":"2019","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/coa.13150","article-title":"Otitis media with effusion in aspirin-exacerbated respiratory disease patients-A series of 22 cases","volume":"43","author":"Hafren","year":"2018","journal-title":"Clin Otolaryngol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.wjorl.2018.08.001","article-title":"Pathogenesis of NSAID-induced reactions in aspirin-exacerbated respiratory disease","volume":"4","author":"Laidlaw","year":"2018","journal-title":"World J Otorhinolaryngol Head Neck Surg."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jaip.2016.12.027","article-title":"Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease","volume":"5","author":"Stevens","year":"2017","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B13","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S1081-1206(10)62084-4","article-title":"The natural history and clinical characteristics of aspirin-exacerbated respiratory disease","volume":"89","author":"Berges-Gimeno","year":"2002","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/alr.22471","article-title":"Treatment practices for aspirin-exacerbated respiratory disease: analysis of a national insurance claims database","volume":"10","author":"Roland","year":"2020","journal-title":"Int Forum Allergy Rhinol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1177\/1945892418770260","article-title":"Long-term clinical outcomes of aspirin desensitization with continuous daily aspirin therapy in aspirin-exacerbated respiratory disease","volume":"32","author":"Walters","year":"2018","journal-title":"Am J Rhinol Allergy."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.pec.2015.06.022","article-title":"Shared decision making: concepts, evidence, and practice","volume":"98","author":"Stiggelbout","year":"2015","journal-title":"Patient Educ Couns."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMp1500523","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N Engl J Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/02770903.2018.1490754","article-title":"Depression symptoms and quality of life among individuals with aspirin-exacerbated respiratory disease","volume":"56","author":"Feldman","year":"2019","journal-title":"J Asthma."},{"key":"B20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.4193\/Rhin19.430","article-title":"The Burden of Non-steroidal anti-inflammatory exacerbated respiratory disease from the patient's perspective - a qualitative analysis of posts from the Samter's Society","volume":"58","author":"Alanin","year":"2020","journal-title":"Rhinology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.wjorl.2020.07.006","article-title":"Endoscopic sinus surgery and aspirin desensitization improve otologic-specific SNOT-22 scores","volume":"6","author":"Naples","year":"2020","journal-title":"World J Otorhinolaryngol Head Neck Surg."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.3758\/s13428-017-0997-0","article-title":"General mixture item response models with different item response structures: exposition with an application to Likert scales","volume":"50","author":"Tijmstra","year":"2018","journal-title":"Behav Res Methods."},{"key":"B23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/ijms21249477","article-title":"Monoclonal antibodies and airway diseases","volume":"21","author":"Lyly","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.jaip.2015.03.001","article-title":"Survey-defined patient experiences with aspirin-exacerbated respiratory disease","volume":"3","author":"Ta","year":"2015","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/lary.24220","article-title":"Aspirin sensitivity does not compromise quality-of-life outcomes in patients with Samter's triad","volume":"124","author":"Jang","year":"2014","journal-title":"Laryngoscope."},{"key":"B26","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jaip.2016.10.021","article-title":"Current knowledge and management of hypersensitivity to aspirin and NSAIDs","volume":"5","author":"Laidlaw","year":"2017","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jaci.2020.11.001","article-title":"Inflammatory heterogeneity in aspirin-exacerbated respiratory disease","volume":"147","author":"Scott","year":"2021","journal-title":"J Allergy Clin Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jaci.2020.08.007","article-title":"Heterogeneity of lower airway inflammation in patients with NSAID-exacerbated respiratory disease","volume":"147","author":"Jakiela","year":"2021","journal-title":"J Allergy Clin Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaci.2016.05.048","article-title":"Automated identification of an aspirin-exacerbated respiratory disease cohort","volume":"139","author":"Cahill","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4193\/Rhin20.601","article-title":"Executive summary of EPOS 2020 including integrated care pathways","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology."}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2021.716169\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T05:32:49Z","timestamp":1626327169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2021.716169\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,15]]},"references-count":30,"alternative-id":["10.3389\/falgy.2021.716169"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2021.716169","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,15]]},"article-number":"716169"}}